Executive Summary
NDC12 is no longer just a regulatory topic pharmaceutical companies to monitor. With the new 12-digit National Drug Code format now defined and an effective date established, the focus is shifting from awareness to execution. FDA’s final rule adopts a uniform 12-digit format the National Drug Code, with a 6-digit labeler code, 4-digit product code, and 2-digit package code. FDA states that during the seven-year period before the rule takes effect, March 5, 2026 through March 6, 2033, it will continue to assign 10-digit NDCs, then begin assigning and converting to the uniform 12-digit format on the effective date.
The challenge is that NDC12 does not belong neatly to one department. Regulatory Affairs may interpret the requirement. Information Technology may update systems. Packaging and Labeling may change artwork and barcodes. Supply Chain may manage inventory and product flows. Finance may need to assess billing, rebates, chargebacks, reimbursement, and reporting dependencies. Commercial teams may need to coordinate product data with customers and channel partners.
External organizations add another layer of complexity. Wholesalers, distributors, third-party logistics providers, technology vendors, contract manufacturers, data providers, payers, and other trading partners may each have their own transition plans and timelines.
The result is not a traditional compliance project. NDC12 is a cross-functional transformation program that requires coordinated planning, clear ownership, structured governance, dependency management, testing, and controlled execution.
Without this structure, organizations risk creating disconnected workstreams where departments solve their own portion of the transition independently. That can lead to inconsistent data rules, duplicated effort, missed dependencies, late system changes, partner misalignment, and operational disruption.
This white paper introduces a practical framework planning and executing NDC12 as an enterprise program. The recommended approach follows seven stages: Mobilize → Assess → Design → Plan → Execute → Validate → Transition. The objective is to give pharmaceutical companies a repeatable way to move from regulatory understanding to enterprise readiness while maintaining control across functions, systems, products, and external partners.
SCW helps pharmaceutical companies establish an NDC12 readiness roadmap across impacted systems, product data, labeling, supply chain operations, external partners, testing, cutover, and governance. Schedule an NDC12 readiness discussion.
